ProQR Reports Wider Q1 Loss and Significant Revenue Miss; Pipeline Advances with Extended Cash Runway

summarizeSummary

ProQR Therapeutics announced Q1 2026 results with a wider net loss and revenue significantly below expectations, but highlighted reduced cash burn, an extended cash runway into mid-2027, and ongoing pipeline advancements.

check_boxKey Events

• Q1 2026 Financial Performance

  The company reported a net loss of €13.4 million for Q1 2026, an increase from €10.1 million in Q1 2025. Revenue for the quarter was €2.03 million, significantly missing analyst estimates of €5.25 million.

• Reduced Cash Burn and Extended Runway

  Net cash used in operating activities decreased to €11.1 million in Q1 2026 from €15.8 million in Q1 2025. ProQR ended the quarter with €81.1 million in cash and cash equivalents, providing a runway into mid-2027.

• Pipeline Advancement and Upcoming Milestones

  AX-0810 target engagement data in healthy volunteers is on track for Q2 2026, with biliary atresia selected as the initial Phase 2 indication for an investigator-initiated trial in China (data targeted H1 2027). Other programs (AX-0811, AX-0422, AX-2911) are advancing towards CTA filings and initial clinical data in 2026-2027.

• Axiomer Platform Development

  ProQR continues to enhance its Axiomer™ RNA editing platform through AI-enabled discovery, including a strategic partnership with Ginkgo Bioworks and the formation of an AI Advisory Board.

auto_awesomeAnalysis

ProQR Therapeutics reported a significant increase in net loss and revenue that substantially missed analyst estimates for Q1 2026. This financial underperformance is a strong negative signal. However, the company also demonstrated a reduced cash burn and confirmed a cash runway into mid-2027, which is critical for a clinical-stage biotech. Additionally, ProQR provided updates on its pipeline, including upcoming clinical data for AX-0810 and the advancement of several other programs, offering future catalysts.